Viral reservoirs an impediment to HAART: New strategies to eliminate HIV-1

Current Drug Targets - Infectious Disorders

Volumn 3, Issue 2, 2003, Pages 179-206

  Saksena, Nitin K ^a   Haddad, Da'ed N ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

AIDS; Gene therapy; HAART; HIV; Immune therapy; Natural therapeutics; New anti HIV drugs; Viral reservoirs

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); AMPRENAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATEVIRDINE; CD4 IMMUNOGLOBULIN G2; CYANOVIRIN N; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; INTEGRASE INHIBITOR; L 870812; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NEVIRAPINE; PRO 2000; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SC 351125; STAVUDINE; T 1249; TENOFOVIR; TENOFOVIR DISOPROXIL; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TISSUE LEVEL; GENE THERAPY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LIVER TOXICITY; MACROPHAGE; MONOCYTE; RESERVOIR; REVIEW; T LYMPHOCYTE; TASTE DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS LATENCY; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION;

EID: 0038135030     PISSN: 15680053     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568005033481187     Document Type: Review

References (372)

1. Mallal, S. Antivir. Ther., 2001, 6 Suppl. 2, 21.
2. Puzantian, T. Pharmacotherapy., 2002, 22, 930.
3. Moyle, G. AIDS Read., 2002, 12, 344.
4. Powderly, W.G. J. Acquir. Immune Defic. Syndr., 2002, 31 Suppl. 1, S3.
5. Blankson, J.N.; Persaud, D.; Siliciano, R.F. Annu. Rev. Med., 2002, 53, 557.
6. Kerza-Kwiatecki, A.P.; Amini, S. J. Neurovirol., 1999, 5, 113.
7. Pomerantz, R.J. Curr. Opin. Investig. Drugs, 2002, 3, 1133.
8. Potter, S.J.; Dwyer, D.E.; Saksena, N.K. Virol., 2003, 305, 339.
9. Pomerantz, R.J. Clin. Lab. Med., 2002, 22, 651.
10. Worgall, S.; Connor, R.; Kaner, R.J.; Fenamore, E.; Sheridan, K.; Singh, R.; Crystal, R.G. J. Virol., 1999, 73, 5865.
11. Wang, B.; Dyer, W.B.; Zaunders, J.J.; Mikhail, M.; Sullivan, J.S.; Williams, L.; Haddad, D.N.; Harris, G.; Holt, J.A.; Cooper, D.A.; Miranda-Saksena, M.; Boadle, R.; Kelleher, A.D.; Saksena, N.K. Virol., 2002, 304, 246.
12. Brodie, S.J.; de la Rosa, C.; Howe, J.G.; Crouch, J.; Travis, W.D.; Diem, K. Am. J. Pathol., 1999, 154, 1453.
13. Lewin-Smith, M.; Wahl, S.M.; Orenstein, J.M. Mod Pathol., 1999, 12, 75.
14. Orenstein, J.M.; Fox, C.; Wahl, S.M. Sci., 1997, 276, 1857.
15. Chun, T.W.; Finzi, D.; Margolick, J.; Chadwick, K.; Schwartz, D. Siliciano, R.F. Nat. Med., 1995, 1, 1284.
16. Chun, T.W.; Stuyver, L.; Mizell, S.B.; Ehler, L.A.; Mican, J.A.; Baseler, M.; Lloyd, A.L.; Nowak, M.A.; Fauci, A.S. Proc. Natl. Acad. Sci. U S A., 1997, 94, 13193.
17. Wong, J.K.; Hezareh, M.; Gunthard, H.F.; Wong, J.K.; Hezareh, M.; Gunthard, H.F.; Havlir, D.V.; Ignacio, C.C.; Spina, C.A.; Richman, D.D. Sci., 1997, 278, 1291.
18. Michie, C.A.; McLean, A.; Alcock, C.; Beverley, P.C. Nat., 1992, 360, 264.
19. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L.M.; Buck, C.; Chaisson, R.E.; Quinn, T.C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D.D.; Richman, D.D.; Siliciano, R.F. Sci., 1997, 278, 1295.
20. Mclean, A.R.; Michie, C.A. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 3707.
21. Imlach, S.; McBreen, S.; Shirafuji, T.; Leen, C.; Bell, J.E.; Simmonds, P. J. Virol., 2001, 75, 11555.
22. Saha, K.; Zhang, J.; Gupta, A.; Dave, R.; Yimen, M.; Zerhouni, B. Nat. Med., 2001, 7, 65.
23. Flamand, L.; Crowley, R.W.; Lusso, P.; Colombini-Hatch, S.; Margolis, D.M.; Gallo, R.C. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 3111.
24. Kitchen, S.G.; Korin, Y.D.; Roth, M.D.; Landay, A.; Zack, J.A. J. Virol., 1998, 72, 9054.
25. Yang, L.P.; Riley, J.L.; Carroll, R.G.; June, C.H.; Hoxie, J.; Patterson, B.K.; Ohshima, Y.; Hodes, R.J.; Delespesse, G. J. Exp. Med, 1998, 187, 1139.
26. Walker, B.D.; Flexner, C.; Birch-Limberger, K.; Fisher, L.; Paradis, T.J.; Aldovini, A.; Young, R.; Moss, B.; Schooley, R.T. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 9514.
27. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Sci., 1995, 27, 1811.
28. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Choe, S.; Unutmaz, D.; Burkhart, M.; DiSchall, T.J.; Littman, D.R.; Landau, N.R. Nat., 1996, 381, 661.
29. Furtado, M.R.; Callaway, D.S.; Phair, J.P.; Kunstman, K.J.; Stanton, J.L.; Macken, C.A.; Perelson. A.S.; Wolinsky, S.M. N. Engl. J. Med., 1999, 340, 1614.
30. Gartner, S.; Markovits, P.; Markovitz, D.M.; Kaplan, M.H.; Gallo, R.C.; Popovic, M. Sci., 1986, 233, 215.
31. Ho, D.D.; Rota, T.R.; Hirsch, M.S. J. Clin. Invest., 1986, 7, 1712.
32. Koenig, S.; Gendelman, H.E.; Orenstein, J.M.; Dal Canto, M.C.; Pezeshkpour, G.H.; Yungbluth, M.; Janotta, F.; Aksamit, A.; Martin, M.A.; Fauci, A.S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Sci., 1986, 233, 1089.
33. Meltzer, M.S.; Nakamura, M.; Hansen, B.D.; Turpin, J.A.; Kalter, D.C.; Gendelman, H.E. AIDS Res. Hum. Retrovir., 1990, 6, 967.
34. Perelson, A.S.; Essunger, P.; Cao, Y.; Vesanen, M.; Hurley, A.; Saksela, K.; Markowitz, M.; Ho, D.D. Nat., 1997, 387, 188.
35. Perelson, A.S.; Neumann, A.U.; Markowitz, M.; Leonard, J.M.; Ho, D.D. Sci., 1996, 271, 1582.
36. Van Furth, R. Curr. Top. Pathol., 1989, 79, 125.
37. Embretson, J.; Zupancic, M.; Ribas, J.L.; Burke, A.; Racz, P.; Tenner-Racz, K.; Haase, A.T. Nat., 1993, 362, 59.
38. Perno, C.F.; Newcomb, F.M.; Davis, D.A.; Aquaro, S.; Humphrey, R.W.; Calio, R.; Yarchoan, R.J. Infect Dis., 1998, 178, 413.
39. Kaczorowski, S.; Ochocka, M.; Kaczorowska, M.; Aleksandrowicz, R.; Matysiakl, M.; Karwacki, M. Leuk. Lympho., 1995, 20, 143.
40. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.; Roden D.M.; Wilkinson G.R. J. Clin. Invest., 1998, 101, 289.
41. Cameron, P.U.; Freudenthal, P.S.; Barker, J.M.; Gezelter, S.; Inaba, K.; Steinman, R.M. Sci., 1992, 257, 383.
42. Pope, M.; Betjes, M.G.; Romani, N.;Pope, M.; Betjes, M.G.; Romani, N.; Hirmand, H.; Cameron, P.U.; Hoffman, L.; Gezelter, S.; Schuler, G.; Steinman, R.M. Cell, 1994, 78, 389.
43. Canque, B.; Bakri, Y.; Camus, S.; Yagello, M.; Benjouad, A.; Gluckman, J.C. Blood, 1999, 93, 3866.
44. Kawamura, T.; Cohen, S.S.; Borris, D.L.; Aquilino, E.A.; Glushakova, S.; Margolis, L.B.; Orenstein, J.M.; Offord, R.E.; Neurath, A.R.; Blauvelt, A. J. Exp. Med. 2000, 192, 1491.
45. Zambruno, G.; Mori, L.; Marconi, A.; Mongiardo, N.; De Rienzo B.; Bertazzoni U.; Giannetti, A. J. Invest. Dermatol. 1991, 96, 979.
46. Malaspina, A.; Moir, S.; Nickle D.C.; Donoghue, E.T.; Ogwaro, K.M.; Ehler, L.A.; Liu, S.; Mican, J.A.; Dybul, M.; Chun, T.W.; Mullins, J.I.; Fauci, A.S. J. Virol., 2002, 76, 8855.
47. Cavert, W., Notermans, D.W.; Staskus, K.; Wietgrefe, S.W.; Zupancic, M.; Gebhard, K.; Henry, K.; Zhang, Z.Q.; Mills, R.; McDade, H.; Schuwirth, C.M.; Goudsmit, J.; Danner, S.A.; Haase, A.T. Sci., 1997, 276, 960.
48. Picker, L.J.; Siegelman, M.H. Lymphoid tissues and organs. In Paul WE, ed. Fundament Immunol. 3rd ed.; New York, NY: Raven Press Ltd; 1993, 145-197.
49. Fox, C.H.; Tenner-Racz, K.; Racz, P.; Firpo, A.; Pizzo, P.A.; Fauci, A.S. J. Infect. Dis., 1991, 164, 1051.
50. Pantaleo, G.; Graziosi, C.; Demarest, J.F.; Butini, L.; Montroni, M.; Fox, C.H.; Orenstein, J.M.; Kotler, D.P.; Fauci, A.S. Nat., 1993, 362, 355.
51. Schacker, T.; Little, S.; Connick, E.; Gebhard-Mitchell, K.; Zhang, Z.Q.; Krieger, J.; Pryor, J.; Havlir, D.; Wong, J.K.; Richman, D.; Corey, L.; Haase, A.T. J. Infect. Dis., 2000, 181, 354.
52. Cohen, O.J.; Pantaleo, G.; Holodniy, M.; Fox, C.H.; Orenstein, J.M.; Schnittman, S.; Niu, M.; Graziosi, C.; Pavlakis, G.N.; Lalezari, J.; Bartlett, J.A. J. Infect. Dis., 1996, 173, 849.
53. Wong, J.K.; Gunthard, H.F.; Havlir, D.V.; Zhang, Z.Q.; Haase, A.T.; Ignacio, C.C.; Kwok, S.; Emini, E.; Richman, D.D. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 12574.
54. Burton, G.; Keele, B.; Estes, J.; Thacker, T.; Gartner, S. Semin. Immunol., 2002, 14, 275.
55. Valentin, A.; Rosati, M.; Patenaude, D.J.; Hatzakis, A.; Kostrikis, L.G.; Lazanas, M.; Wyvill, K.M.; Yarchoan, R.; Pavlakis, G.N. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 7015.
56. Srinivas, R.V.; Middlemas, D.; Flynn, P.; Fridland, A. Antimicrob. Agents. Chemother. 1998, 42, 3157.
57. Maehlen, J.; Dunlop, O.; Liestol, K.; Dobloug, J.H.; Goplen, A.K.; Torvik, A. AIDS, 1995, 9, 1165.
58. Zack, J.A.; Arrigo, S.J.; Weitsman, S.R.; Go, A.S.; Haislip, A.; Chen, I.S. Cell, 1990, 61, 213.
59. Pantaleo, G.; Graziosi, C.; Fauci, A.S. AIDS, 1993, 7, S19.
60. Parrott, D.M.; Wilkinson, P.C. Prog. Allerg., 1981, 28, 193.
61. Poli, G.; Fauci, A.S. AIDS Res. Hum. Retroviru., 1992, 8, 191.
62. Emilie, D.; Peuchmaur, M.; Maillot, M.C.; Crevon, M.C.; Brousse, N.; Delfraissy, J.F.; Dormont, J.; Galanaud, P. J. Clin. Invest., 1990, 86, 148.
63. Pantaleo, G.; Graziosi, C.; Fauci, A.S. N. Engl. J. Med., 1993, 328, 327.
64. Spiegel, H.; Herbst, H.; Niedobitek, G.; Foss, H.D.; Stein, H. J. Pathol., 1992, 140, 15.
65. Tenner-Racz, K.; Racz, P.; Bofill, M.; Schulz-Meyer, A.; Dietrich, M.; Kern, P.; Weber, J.; Pinching, A.J.; Veronese-Dimarzo, F.; Popovic, M. Am. J. Pathol., 1986, 123, 9.
66. Biberfeld, P.; Chayt, K.J.; Marselle, L.M.; Biberfeld, G.; Gallo, R.C.; Harper, M.E. Am. J. Pathol., 1986, 125, 436.
67. Pantaleo, G.; Graziosi, C.; Butini, L.; Pizzo, P.A.; Schnittman, S.M.; Kotler, D.P.; Fauci, A.S. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 9838.
68. Stellbrink, H.J.; Eggers, C.; van Lunzen, J.; Albrecht, H.; Greten, H. AIDS, 1997, 11, 1655.
69. Tenner-Racz, K.; Stellbrink, H.J.; van Lunzen, J.; Schneider, C.; Jacobs, J.P.; Raschdorff, B.; Grosschupff, G.; Steinman, R.M.; Racz, P. J. Exp. Med., 1998, 187, 949.
70. Lafeuillade, A.; Poggi, C.; Profizi, N.; Tamalet, C.; Costes, O. J. Infect. Dis., 1996, 174, 404.
71. Manouilov, K.K.; White, C.A.; Boudinot, F.D.; Fedorov, I.I.; Chu, C.K. Drug. Metab. Dispos., 1995, 23, 655.
72. Cohen, O.J.; Pantaleo, G.; Holodniy, M.; Schnittman, S.; Niu, M.; Graziosi, C.; Pavlakis, G.N.; Lalezari, J.; Bartlett, J.A.; Steigbigel, R.T. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 6017.
73. Lafeuillade, A.; Tamalet, C.; Poggi, C.; Pellegrino, P.; Tourres, C.; Izopet, J. AIDS, 1997, 11, 67.
74. Chang, J.; Jozwiak, R.; Wang, B.; Ng, T.; Ge, Y.C.; Bolton, W.; Dwyer, D.E.; Randle, C.; Osborn, R.; Cunningham, A.L.; Saksena, N.K. AIDS. Res. Hum. Retrovirus., 1998, 14, 25.
75. Saksena, N.K.; Wang, B.; Ge, Y.C.; Chang, J.; Dwyer, D.E.; Xiang, S.H.; Packham, D.R.; Randle, C.; Cunningham, A.L. AIDS. Res. Hum. Retrovirus., 1997, 13, 111.
76. Smit, T.K.; Wang, B.; Ng, T.; Osborne, R.; Brew, B.; Saksena, N.K. Virol., 2001, 279, 509.
77. Lipton, S.A. Treating AIDS dementia. Sci., 1997, 276, 1629.
78. Pialoux, G.; Fournier, S.; Moulignier, A.; Poveda, J.D.; Clavel, F.; Dupont, B. AIDS, 1997, 11, 1302.
79. Kure, K.; Llena, J.F.; Lyman, W.D.; Soeiro, R.; Weidenheim, K.M.; Hirano, A.; Dickson, D.W. Hum. Pathol., 1991, 22, 700.
80. Pratt, R.D.; Nichols, S.; McKinney, N.; Kwok, S.; Dankner, W.M.; Spector, S.A. J. Infect Dis., 1996, 174, 288.
81. Ellis, R.J.; Seubert, P.; Motter, R.; Galasko, D.; Deutsch, R.; Heaton, R.K.; Heyes, M.P.; McCutchan, J.A.; Atkinson, J.H.; Grant, I. HIV Neurobehavioral Research Center Group (HNRC). Neurosci. Lett., 1998, 254, 1.
82. Sei, S.; Stewart, S.K.; Farley, M.; Mueller, B.U.; Lane, J.R.; Robb, M.L.; Brouwers, P.; Pizzo, P.A. J. Infect. Dis., 1996, 174, 1200.
83. Kakuda, T.N.; Struble, K.A.; Piscitelli, S.C. Am. J. Health. Syst. Pharm., 1998, 55, 233.
84. Lin, J.H.; Chiba, M.; Balani, S.K.; Chen, I.W.; Kwei, G.Y.; Vastag, K.J.; Nishime, J.A. Drug Metab. Dispos., 1996, 24, 1111.
85. Sawchuk, R.J.; Yang, Z. Drug Deliv. Rev., 1999, 39, 5.
86. Pomerantz, R.J.; Kuritzkes, D.R.; de la Monte, S.M.; Rota, T.R.; Baker, A.S.; Albert, D.; Bor, D.H.; Feldman, E.L.; Schooley, R.T.; Hirsch, M.S. N. Engl. J. Med., 1987, 317, 1643.
87. Cunningham, P.; Smith, D.; Satchell, C.; Cooper, D.A.; Brew, B. In vivo comparison of RT inhibitor resistance patterns in paired cerebrospinal fluid and blood of HIV-1 infected patients with a novel line probe assay. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections; February 1-5, 1998; Chicago Ill. Abstract 682.
88. Burger, D.M.; Kraaijeveld, C.L.; Meenhorst, P.L.; Mulder, J.W.; Koks, C.H.; Bult, A.; Beijnen, J.H. AIDS, 1993, 7, 1581.
89. Gallo, J.M.; Etse, J.T.; Doshi, K.J.; Boudinot, F.D.; Chu, C.K. Pharm. Res., 1991, 8, 247.
90. Klecker, R.W. Jr.; Collins, J.M.; Yarchoan, R.C.; Thomas, R.; Jenkins, J.F.; Broder, S.; Myers, C.E. Clin. Pharmacol. Ther., 1987, 41, 407.
91. Tartaglione, T.A.; Collier, A.C.; Coombs, R.W.; Opheim, K.E., Cummings, D.K.; Mackay, S.R.; Benedetti, J.; Corey, L. Arch. Neurol., 1991, 48, 695.
92. Rolinski, B.; Bogner, J.R.; Sadri, L; Wintergerst, U.; Goebel, F.D. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1997, 15, 192.
93. Balis, F.M.; McCully, C.; Gough, L.; Pizzo, P.A.; Poplack, D.G. Antimicrob. Agents Chemother., 1989, 33, 810.
94. Brouwers, P.; Hendricks, M.; Lietzau, J.A.; Pluda, J.M.; Mitsuya, H.; Broder, S.; Yarchoan, R. AIDS, 1997, 11, 59.
95. Gisslen, M.; Norkrans, G.; Svennerholm, B.; Hagberg, L. J. Infect. Dis., 1997, 175, 434.
96. Tozzi, V.; Narciso, P.; Galgani, S.; Sette, P.; Balestra, P.; Gerace, C.; Pau, F.M.; Pigorini, F.; Volpini, V.; Camporiondo, M.P. AIDS., 1993, 7, 683.
97. Bell, J.E.; Donaldson, Y.K.; Lowrie, S.; Bell, J.E.; Donaldson, Y.K.; Lowrie, S.; McKenzie, C.A.; Elton, R.A.; Chiswick, A.; Brettle, R.P.; Ironside, J.W.; Simmonds, P. AIDS, 1996, 10, 493.
98. Galinsky, R.E.; Hoesterey, B.L.; Anderson, B.D. Life Sci., 1990, 47, 781.
99. Hedaya, M.A.; Sawchuk, R.J. J. Pharm. Sci., 1989, 78, 716.
100. Masereeuw, R.; Jaehde, U.; Langemeijer, M.W.; de Boer, A.G.; Breimer, D.D. Pharm. Res., 1994, 11, 324.
101. Sawchuk, R.J.; Hedaya, M.A. Pharm. Res., 1990, 7, 332.
102. Takasawa, K.; Terasaki, T.; Suzuki, H.; Ooie, T.; Sugiyama, Y. J. Pharmacol. Exp. Ther., 1997, 282, 1509.
103. Takasawa, K.; Terasaki, T.; Suzuki, H.; Sugiyama, Y. J. Pharmacol. Exp. Ther. 1997, 281, 369.
104. Tuntland, T.; Ravasco, R.J.; al-Habet, S.; Unadkat, J.D. Pharm. Res., 1994, 11, 312.
105. Wang, Y.; Sawchuk, R.J. J. Pharm. Sci., 1995, 84, 871.
106. Wang, Y.; Wong, S.L.; Sawchuk, R.J. Pharm. Res., 1993, 10, 1411.
107. Wong, S.L.; Van Belle, K.; Sawchuk, R.J. J. Pharmacol. Exp. Ther., 1993, 264, 899.
108. Wong, S.L.; Wang, Y.; Sawchuk, R.J. Pharm. Res., 1992, 9, 332.
109. Dykstra, K.H.; Arya, A.; Arriola, D.M.; Bungay, P.M.; Morrison, P.F.; Dedrick, R.L. J. Pharmacol. Exp. Ther., 1993, 267, 1227.
110. Thomas, S.A.; Segal, M.B. J. Pharmacol. Exp. Ther., 1997, 281, 1211.
111. Hartman, N.R.; Yarchoan, R.; Pluda, J.M.; Thomas, R.V.; Marczyk, K.S.; Broder, S.; Johns, D.G. Clin. Pharmacol. Ther., 1990, 47, 647.
112. Hawkins, M.E.; Mitsuya, H.; McCully, C.M.; Godwin, K.S.; Murakami, K.; Poplack, D.G.; Balis, F.M. Antimicrob. Agents. Chemother., 1995, 39, 1259.
113. Hoesterey, B.L.; Galinsky, R.E.; Anderson, B.D. Drug Metab. Dispos., 1991, 19, 907.
114. Morgan, M.E.; Chi, S.C.; Murakami, K.; Mitsuya, H.; Anderson, B.D. Antimicrob. Agents. Chemother., 1992, 36, 2156.
115. Singhal, D.; Morgan, M.E.; Anderson, B.D. Pharm. Res., 1997, 14, 786.
116. Wientjes, M.G.; Placke, M.E.; Chang, M.J.; Page, J.G.; Kluwe, W.M.; Tomaszewski, J.E. Invest. New Drugs, 1991, 9, 159.
117. Galinsky, R.E.; Flaharty, K.K.; Hoesterey, B.L.; Anderson, B.D. J. Pharmacol. Exp. Ther., 1991, 257, 972.
118. Anderson, B.D.; Hoesterey, B.L.; Baker, D.C.; Galinsky, R.E. J. Pharmacol. Exp. Ther., 1990, 253, 113.
119. Ahluwalia, G.; Cooney, D.A.; Mitsuya, H.; Fridland, A.; Flora, K.P.; Hao, Z.; Dalal, M.; Broder, S.; Johns, D.G. Biochem. Pharmacol., 1987, 36, 3797.
120. Klecker, R.W. Jr.; Collins, J.M.; Yarchoan, R.C.; Thomas, R.; McAtee, N.; Broder, S.; Myers, C.E. J. Clin. Pharmacol., 1988, 28, 837.
121. van Leeuwen, R.; Katlama, C.; Kitchen, V.; Boucher, C.A.; Tubiana, R.; McBride, M.; Ingrand, D.; Weber, J.; Hill, A.; McDade, H. J. Infect. Dis., 1995, 171, 1166.
122. Dudley, M.N.; Graham, K.K.; Kaul, S.; Geletko, S.; Dunkle, L.; Browne, M.; Mayer, K. J. Infect. Dis., 1992, 166, 480.
123. Haworth, S.J.; Christofalo, B.; Anderson, R.D.; Dunkle L.M. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1998, 17, 235.
124. Kline, M.W.; Dunkle, L.M.; Church, J.A. Pediat., 1999, 96, 247.
125. Rutschmann, O.; Hirschel, B. Schweiz. Med. Wochenschr., 1997, 127, 436.
126. Glynn, S.L.; Yazdanian, M. J. Pharm. Sci., 1998, 87, 306.
127. Brew, B.J.; Dunbar, N.; Druett, J.A.; Freund, J. AIDS, 1996, 10, 1357.
128. Filippi, C.G.; Sze, G.; Farber, S.J.; Shahmanesh, M.; Selwyn, P.A. Radiol., 1998, 206, 491.
129. Ferrando, S.; van Gorp, W.; McElhiney, M.; Goggin, K.; Sewell, M.; Rabkin, J AIDS, 1998, 12, F65.
130. Gendelman, H.E.; Zheng, J.; Coulter, C.L.; Ghorpade, A.; Che, M.; Thylin, M.; Rubocki, R.; Persidsky, Y.; Hahn, F.; Reinhard, J. Jr.; Swindells, S. J. Infect. Dis. 1998, 178, 1000.
131. Eggers, C.C.; van Lunzen, J.; Buhk, T.; Stellbrink, H.J. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1999, 20, 259.
132. Chien, J.W.; Valdez, H.; McComsey, G.; McClernon, D.; St Clair, M.; Lederman, M.M. J. Acquir. Immune. Defic. Syndr., 1999, 21, 277.
133. Venturi, G.; Catucci, M.; Romano, L.; Corsi, P.; Leoncini, F.; Valensin, P.E.; Zazzi, M. J. Infect. Dis., 2000, 181, 740.
134. Wildemann, B.; Haas, J.; Ehrhart, K.; Wagner, H.; Lynen, N.; Storch-Hagenlocher, B. Neurol., 1993, 43, 2659.
135. Bourinbaiar, A.S.; Phillips, D.M. J. Acquir. Immune. Defic. Syndr., 1991, 4, 56.
136. Cerf-Bensussan, N.; Guy-Grand, D. Gastroenterol. Clin. N. Am., 1991, 20, 549.
137. Ullrich, R.; Schieferdecker, H.L.; Ziegler, K.; Riecken, E.O.; Zeitz, M. Cell Immunol., 1990, 128, 619.
138. Schnittman, S.M.; Lane, H.C.; Greenhouse, J.; Justement, J.S.; Baseler, M.; Fauci, A.S. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 6058.
139. Anton, P.A.; Elliott, J.; Poles, M.A.; McGowan, I.M.; Matud, J.; Hultin, L.E.; Grovit-Ferbas, K.; Mackay, C.R.; Chen, I.S.Y.; Giorgi, J.V. AIDS, 2000, 14, 1761.
140. Poles, M.A.; Elliott, J.; Taing, P.; Anton, P.A.; Chen, I.S. J. Virol., 2001, 75, 8390.
141. Clayton, F.; Snow, G.; Reka, S.; Kotler, D.P. Clin. Exp. Immunol., 1997, 107, 288.
142. Lim, S.G.; Condez, A.; Lee, C.A.; Johnson, M.A.; Elia, C.; Poulter, L.W. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin. Exp. Immunol., 1993, 92, 448.
143. Schneider, T.; Jahn, H.U.; Schmidt, W.; Riecken, E.O.; Zeitz, M.; Ullrich, R. Berlin Diarrhea/Wasting Syndrome Study Group. Gut, 1995, 37, 524.
144. Veazey, R.S.; DeMaria, M.; Chalifoux, L.V.; Shvetz, D.E.; Pauley, D.R.; Knight, H.L.; Rosenzweig, M.; Johnson, R.P.; Desrosiers, R.C.; Lackner, A.A. Sci., 1998, 280, 427.
145. Barnett, S.W.; Barboza, A.; Wilcox, C.M.; Forsmark, C.E.; Levy, J.A. Virol., 1991, 182, 802.
146. al-Mulla, W.; Church, D.; Gill, M.J. HIV/GI Research Study Group. J. Med Virol., 1997, 52, 31.
147. van der Hoek, L.; Sol, C.J.; Snijders, F.; Bartelsman, J.F.; Boom, R.; Goudsmit, J. J. Gen. Virol., 1996, 77, 2415.
148. van der Hoek, L.; Sol, C.J.; Maas, J.; Lukashov, V.V.; Kuiken, C.L.; Goudsmit, J. J. Gen. Virol. 1998, 79, 259.
149. Poles, M.A.; Elliott, J.; Vingerhoets, J.; Michiels, L.; Scholliers, A.; Bloor, S.; Larder, B.; Hertogs, K.; Anton, P.A. J. Infect. Dis., 2001, 183, 143.
150. Schlegel, P.N.; Chang, S.KIn: Campbell's Urology; Walsh, P.C.; Retik, A.B.; Vaughan, E.D, Wein, A.J. eds. 7th vol. Pa: WB Saunders Co; Philadelphia, 1998, 1254-1286.
151. Eyre R.C.; Zheng G.; Kiessling A.A. Urol., 2000, 55, 591.
152. Pomerantz R.J. HIV-1 in seminal fluid and cervical secretions: potential reservoirs for HIV-1 in vivo. In: Program and abstracts of the 5th conference on retroviruses and opportunistic infections; February 1-5, 1998, Chicago, Ill. Abstract 562.
153. Scofield, V.L. Sperm as infection-potentiating cofactors in HIV transmission. J. Reprod. Immunol., 1998, 41(1-2), 359.
154. Steibegel, R. 2001. Available at: http://www.uhmc.sunysb.edu/microbiology/hivaids.html.
155. Finzi, D.; Blankson, J.; Siliciano, J.D.; Margolick, J.B.; Chadwick, K.; Pierson, T.; Smith, K.; Lisziewicz, J.; Lori, F.; Flexner, C.; Quinn, T.C.; Chaisson, R.E.; Rosenberg, E.; Walker, B.; Gange, S.; Gallant, J.; Siliciano, R.F. Nat. Med., 1999, 5, 512.
156. Michael, N.L.; Moore, J.P. Nat. Med., 1999, 5, 1330
157. Horn, T. Entry and fusion inhibitors: an update; Cohen, C. and Moore, J. Ed.; Reprinted from the PRN notebook, 2002, 7, 16.
158. Horn, T. In New Antiretrovirals in Development: the View in 2002; Hammer, S. Ed.; Reprinted from the PRN Notebook, 2002, 7,16.
159. Wainberg, M.A. New treatments and targets; The body Covers; The 6th International Congress on drug therapy in HIV infection., 2002.
160. Deen, K.C.; McDougal, J.S.; Inacker, R.; Folena-Wasserman,G.; Arthos, J.; Rosenberg, J.; Maddon, P.J.; Axel, R.; Sweet, R.W. Nat., 1988, 331, 82.
161. Capon, D.J.; Ward, R.H.R. Curr Opin in Immuno., 1990, 2, 433.
162. Callahan, L.N.; Norcross, M.A. Lanc., 1989, 2(8665), 734.
163. Daar, E.S.; Li, X.L., Moudgil, T.; Ho, D.D. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 6574.
164. Schacker, T.; Collier, A.C.; Coombs, R.; Unadkat, J.D.; Fox, I.; Alam, J.; Wang, J.P.; Eggert, E.; Corey, L. J. Acq. Immuno Def. Synd. Hum. Retroviral., 1995, 9, 145.
165. amfAR AIDS research, amfAR global link, © 2002 American foundation for AIDS research. Available at: http://www.amfar.org/
166. Gulick, R.M. In Topics in HIV-Medicine: A publications of the international AIDS society-USA, 2002, 10, 14.
167. Koot, M.; Keet, I.; Vos, A.H.; de Goede, R.E.; Roos, M.T.; Coutinho, R.A.; Miedema, F.; Schellekens, P.T.; Tersmette, M. Ann. Intern. Med., 1993, 118, 681.
168. Mosier, D.E.; Picchio, G.R.; Gulizia, R.J.; Sabbe, R.; Poignard, P.; Picard, L.; Offord, R.E.; Thompson, D.A.; Wilken. J. Virol., 1999, 73, 3544.
169. Trkola, A.; Kuhmann, S.E.; Strizki, J.M.; Maxwell, E.; Ketas, T.; Morgan, T.; Pugach, P.; Xu, S.; Wojcik, L.; Tagat, J.; Palani, A.; Shapiro, S.; Clader, J.W.; McCombie, S.; Reyes, G.R.; Baroudy, B.M.; Moore, J.P. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 395.
170. Molecule of the month, Sch-351125, Available at: http://www.prous.coin/momo/mar_02/momo.html.
171. Strizki, J.M.; Xu, S.; Wagner, N.E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Tagat, J.R.; McCombie, S.; Cox, K.; Fawzi, A.B.; Chou, C.C.; Pugliese-Sivo, C.; Davies, L.; Moreno, M.E.; Ho, D.D.; Trkola, A.; Stoddart, C.A.; Moore, J.P.; Reyes, G.R.; Baroudy, B.M. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 12718.
172. Moore, J. HIV-1 escape from small molecule inhibitors in PBMC does not involve coreceptor switching to CXCR4 use. 1st IAS Conference on HIV Pathogenesis and Treatment, 2001, Buenos Aires, Argentina, Abstract LB-05.
173. Baroudy, B. Coreceptor inhibitor. 14th international AIDS Conference, 2002; Barcelona, Spain; Abstract MoOrAI38.
174. Reynes, J.; Rouzier, R.; Kanouni, T.; Baillat, V.; Baroudy, B.; Keung, A.; Hogan, C.; Markowitz, M.; Laughlin, M. SCH-C: Safety and antiviral effect of a CCR5 receptor antagonist in HIV-1 infected subject 9th conference on retrovirus and opportunistic infections, 2002, Seattle, Washington, Abstract 1.
175. Chen, Z.; Hu, B.; Huang, W.; Strizki, J.; Xu, S.; Wojcik, L.; Whitcomb, J.M.; Zhang, L.; Petropoulos, C.J.; Baroudy, B.; Ho, D. HIV-1 mutants less sustible to SCH-D, a novel small molecule antagonist of CCR5. 9th conference on retroviruses and opportunistic infection, 2002, Seattle, Washington.
176. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. J. Enzyme. Inhib. Med. Chem., 2002, 17, 69.
177. Hendrix, C.W.; Flexner, C.; MacFarland, R.T.; Giandomenico, C.; Fuchs, E.J.; Redpath, E.; Bridger, G.; Henson, G.W. Antimicrob. Agents. Chemother., 2000, 44, 1667.
178. Nadler, J.P.; Oehler, R.L.; Holt, D. Infect. Med., 1998, 15, 113.
179. Kilby, J..M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Matthews, T.; Johnson, M.R.; Nowak, M.A.; Shaw, G.M.; Saag, M.S. Nat. Med., 1998, 4, 1302.
180. Lalezari, J.; Wheeler, D.; Kilby, M.; Wheat, L.J.; Davis, N.; Nieforth, K.; Patel, I. Improved carbonate (CO2) formulation of T20 reduces number of injections required to administer 100mg BID dose. First IAS conference on HIV pathogenesis and treatment, 2001, Buenos Aires, Abstract LB-P20- Poster 1936.
181. Church, J.; Cunningham, C.; Palumbo, P.; Sista, P. for the PACTG 1005 study team. Safety and antiviral activity of chronic subcutaneous administration of T-20 in HIV-1 infected children. 8th Conference on Retroviruses and Opportunistic Infections, 2001, Chicago, Illinois, Abstract 681.
182. Greenberg, M.L.; Sista, P.; Miralles, G.D. Enfuvirtide (T-20) and T-1249 resistance: observation from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a Phase I/II dose-ranging monotherapy trial of T-1249. Antiviral Therapy, 2002, 7, S106-S107. Abstract 128.
183. Eron, J.; Merigan,T.; Kilby, M.; Yangco, B.; Gleavy, J.; Rusnak, P.; Dimassimo, B.; Smith, R.; Baker,B.; Duff, F.; Drucker, J.; Matthews, T and Hopkins, S. for the T1249-101 Study Group. A 14-Day Assessment of the Safety, Pharmacokinetics, and Antiviral Activity of T-1249, a Peptide Inhibitor of Membrane Fusion. 8th Conference on Retroviruses and Opportunistic Infection, 2001, Chicago, Illinois, Abstract 14.
184. Taddeo, B.; Haseltine, W.A.; Farnet, C.M. J. Virol., 1994, 68, 8401.
185. Wiskerchen, M.; Muesing, M.A. J. Virol., 1995, 69, 376.
186. Kresge, K. Integrase inhibitors update, American Foundation of AIDS Research, treatment Directory at: amfAR. Org, August 2002.
187. Pommier, Y.; Neamati, N. In Advances in Viral Research; Maramorosch, K.; Murphy, F.A.; Shatkin, A.J. Eds.; Academic press: New York, 1999.
188. tjh Conference on Retroviruses and Opportunistic infections, 2002: Seattle, Washington, Abstract 8.
189. Fujiwara T. S-1360, a new HIV integrase inhibitor, repeat-dose pharmacokinetics (PK) and safety in healthy volunteers following oral administration. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuPeB4436.
190. Hazuda, D. Antiviral. Ther., 2002, 7(S1), S3. Abstract 1.
191. Jon, H.; Condra.; Miller, M.D.; Hazuda, D.J.; Emini, E.A. Annual. Rev. Med., 2002, 53, 541.
192. AIDS treatment news #373, October 19, 2001. Available at: http://www.aidsinfobbs.org/.
193. Tuske, S.; Sarafianos, S.; Clark, A.D.; Ding, J.; Naeger, L.K.; Miller, M.D.; Gibbs, C.; Jerina, D.M.; Hughes, S.; Arnold, E. Antiviral. Ther., 2001, 6(S1), 42. Abstract 42.
194. Miller, M.D.; Margot, N.A.; Hertogs, K.; Larder, B.; Miller, V.; Nucleos. Nucleot. Nucl. Aci., 2001, 20, 1025.
195. Schinazi, R.F.; Larder, B.A.; Mellors, J.W. Int. Antiviral News., 2000-2001 update, 8, 65.
196. Schütz, M. Quick Reference Guide to new antiretrovirals, from Medscape HIV/AIDS, January 3 2002.
197. Graema Moyle, A review of new antiretroviral drugs in development: Coviracil (emtricitabine; FTC), Internet conference report; 5th International Congress on drug therapy in HIV infection; 2000.
198. Van Der Horst C, Sanne I, Wakeford C, Quinn J, Rousseau F. Two Randomized, Controlled, Equivalence Trials of Emtricitibine (FTC) to Lamivudine (3TC). 8th Conference on Retroviruses and Opportunistic Infections. 2001, Chicago, Illinois. Abstract 18.
199. Mewshaw, J.P.; Myrick, F.T.; Wakefield, D.A.; Hooper, B.J.; Harris, J.L.; McCreedy, B.; Borroto-Esoda, K. Acquir. Immune Defic. Syndr., 2002, 29, 11.
200. Gu, Z.; Wainberg, M.A.; Nguyen-Ba, N.; L'Heureux, L.; de Muys, J.M.; Bowlin, T.L.; Rando, R.F. Antimicrob. Agents Chemother., 1999, 43, 2376.
201. Borroto-Esoda, K.; Mewshow, J.; Wakefield, D. DAPD: a novel nucleoside inhibitor of HIV-1, replication is active against drug-resistant isolates of HIV-1 from patients failing standard nucleoside therapy. 39th Interscience conference on Antimicrobial Agants and Chemotherapy, 1999, San Francisco, Abstract 924.
202. Tremblay CL, Poulin D, Hicks JL, Giguel F, Kollmann C, Chou TC, Hirsch MS. T-20 and DAPD have synergistic in vitro anti-HIV interactions. 9th Conference on Retroviruses and Opportunistic Infections, 2002, Seattle, Washington, Poster 393-T, Abstract F29e.
203. Bethell, R.C.; Allard, B.; De Muys, J.M.; Gu, Z.;Guyen-Ba, N.; Ren, V.; Wainberg, W.A.; Mckenna, P.; and. Taylor, D.L. BCH-13520, a new heterosubstituted nucleoside analogue, is an effective inhibitor of drug resistance HIV-1. 9th Conference on retroviruses and oppertunistic infections, 2002, Seattle, Washington.
204. Erickson-Viitanen, S.; Schinazi, R.F.; Mellors, J.; Geleziunas, R.; Trainor, G.; Wu, J.T.; Gallagher, K.; Klabe, R.; Otto, M.; Pierce, M.E.; Martin, D.E. Novel antiviral chemotherapy agents, 9th Conference on Retroviruses and Opportunistic Infection, 2002, Seattle, Washington.
205. Ruiz, N.; Nusrat, R.; Lauenroth-Mai, E.; et al. Study DPC 083-203, a phase II comparison of a 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. 9th Conference on Retroviruses and opportunistic infections. February 24-28 2002, Seattle, Washington, Abstract 6.
206. Ruiz, N.; Nusrat, R.; Lazzarin, A.; Arasteh, K.; Goebel, F.D.; Audagnotto, S.; Rachlis, A.; Arribas, J.R.; Ploughman, L., Fiske, W., Labriola, D.; Levy, R.; Echols, R. For the DPC 083-201 Study Team. Study DPC 083-201: a phase II double blind (DB) comparison of 3 once daily doses of NNRTI DPC 083 vs 600mg efavirenz (EFV) in combination with two NRTIs in HIV antiretroviral (ARV) treatment-naïve patients. 9th Conference on Retrovirsus and Opportunistic Infections. February 24-28 2002, Seattle, Washington, Abstract 7.
207. Corbett, J.W.; Ko, S.S.; Rodgers, J.D.; Gearhart, L.A.; Magnus, N.A.; Bacheler, L.T.; Diamond, S.; Jeffrey, S.; Klabe, R.M.; Cordova, B.C.; Garber, S.; Logue, K.; Trainor, G.L.; Anderson, P.S.; Erickson-Viitanen, S.K. J. Med. Chem., 2000, 43, 2019.
208. Tibotec-Virco, Product information, Revized September 6, 2002. Available at: http://www.tipotec-virco.com/web/.
209. Gazzard, B.G.; Pozniak, A.; Arasteh, K.; Staszewski, S.; Rozenbaum, W.; Yeni, P.; van 't Klooster, G.; De Dier, K.; Peeters, M. One-week therapy with TMC125, a next generation NNRTI, demonstrates high potency in treatment experienced HIV-1 infected individuals with pheontypic NNRTI-resistance. XIV international AIDS conference, 2002, Barcelona, Abstract TuPeB4438.
210. Gazzard, B.; Pozniak, A.; Arasteh, A.; Staszewski, S.; Rozenbaum, W.; Yeni, P.; van't Klooster, G.; De Dier, K.; Peeters, M.; de Béthune, M.P.; Graham, N.; Pauwels, R. TMC125, a next generation NNRTI, demonstrates high potency after 7 days therapy in treatment experienced HIV-1 infected individuals with pheontypic NNRTI resistance. 9th Conference on Retrovirsus and Opportunistic Infections. February 24-28, 2002, Seattle, Washington, Abstract 4.
211. Gruzdev, B.; Rakhmanova, A.; De Dier, K., Comhaire, S.; Baede-Van Dijk, B.; Van G.; Klooster, T. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART)-naïve, HIV-1 infected subjects. 41st interscience Conference on antimicrobial agents and chemotherapy, 2001, Chicago, Abstract 668.
212. Maugh II, T.H. Times Medical Writer, AIDS scientists fight rising tide of resistance, risky behaviour: health: Researchers find little cause for optimism at conference, see no blockbuster in the pipeline, February 12, 2001. Available at: http://www.aegis.com/news/.
213. de Béthune, M.P.; Azijn, H.; Andries, K.; Janssen, P.; Pauwels, R. Antiviral Ther., 2001, 6(S1), 7.
214. Gruzdev, B.; Horban, A.; Boron-Kaczmarska.; Gille, D.; Van't Klooster, G.; Pauwels, R. TMC120, a New non-nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment naive, HIV-1 infected subjects. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001, Chicago, Illinois. Abstract 13.
215. O'Mara, E.; Mummaneni, V.; Bifano, M.; Randall, D.; Uderman, H.; Knox, L.; Geraldes, M. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, Illinois. Abstract 740.
216. Sanne, I.; Cahn, P.; Percivcal, L.; Phanuphak, P.; Kelleher, T.; Giordano, M.; Pantaleo, G. Comparative results (Phase II 48 weeks): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (A1424-008). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. ICAAC, 2001, Chicago, Abstract-667.
217. Haas, D.; Zala, C.; Schrader, S.; Thiry, A.; McGovern, R.; Schnittman S. Atazanavir plus sequinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol profiles in patients failing prior therapy (Trial A1424-009, week 48). 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002, Seattle, Washington, Abstract 42.
218. Gong, Y.F.; Robinson, B.S.; Rose, R.E.; Deminie, C.; Spicer, T.P.; Stock, D.; Colonno, R.J.; Lin, P.F. Antimicrob. Agents Chemother., 2000, 44, 2319.
219. Colonno, R.J.; Friborg, J.; Rose, R.E.; Lam, E.; Parkin, N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens. Antiviral Ther., 2002, 7, S4. Abstract 4.
220. Larder, B.A.; Hertogs, K.; Bloor, S.; van den Eynde, C.H.; DeCian, W.; Wang, Y.; Freimuth, W.W.; Tarpley, G. AIDS, 2000, 14, 1943.
221. McCallister, S.; Kohlbrenner, V.; Mayers, D. Tipranavir/ritonavir: Derivation of doses that achieve effective plasma concentrations above the IC50 for multiple PI-resistant HIV-1 viruses. XIV international AIDS Conference, 2002, Barcelona, Abstract TuPeB4437.
222. McCallister, S.; Sabo, J.; Mayers, D.L.; Galitz, L. An open label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers (BI 1182.5). 9th Conference on retroviruses and Oppertunistic Infections, 2002, Seattle, Washington, Abstract 434-W.
223. Slater, L.; Farthing, C.; Jayaweera, J.; Para, M.; Haas, D.; Dohnanyi, C.; Kohlbrenner, V.; McCallister, S.; Mayers, D. Safety and efficacy of tipranavir (TPV), a novel non-peptide protease inhibitor, plus ritonavir (RTV), in PI-failure patients. 41st interscience Conference on Antimicrobial Agents and Chemotherapy, 2001, Chicago, Abstract LB-15.
224. Schwartz, R.; Kazanjian, P.; Slater, L.; Hathaway, B.; Markowitz, M.; Wheeler, D.; Goldman, M.; Drulak, M.; McCallister, S.; Mayers, D. 1 Resistance to Tipranavir is Uncommon in a Randomized Trial of Tipranavir/Ritonavir (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections, 2002, Seattle, Abstract 562T.
225. De bethune M.P.; Wigerincki, P.; Jonckheerei, H.; Tahril, A.; Maesi, L.; Pauwelsi, R.; Erickson, J. TMC-114, a highly potent protease inhibitor (PI) with an excellent profile against HIV variants highly resistant to current Pis. 41st Interscience Conference on Antimicrobial
226. De Meyer, S.; Azijn, H.; Van Ginderen, M.; De Bacre, I.; Pauwels, R.; De Bethune, M. In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed protease inhibitors. XI international HIV drug resistance Workshop, 2002, Seville, Abstract 5.
227. Van der Geest, R.; Van der Sandt, I.; Gille, D.; Van Der Geesti, R.; Van Der Sandt, I.; Gille, D.; Groen, K.; Tritsmans, L.; Stoffels, P. Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other Pis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, Chicago, Abstract 1-1934.
228. Erickson, J.; Gulnik, S.; Suvorov, L.; Gustchinal, E.; Xie, D.; Wangl, G.; Eissenstat, M.A.; De Bethune, M.P.; Jonckheere, H.; De Meyer, S.; Azijn, H.; Pauwels, R.; Wigerinck, P.; Surleraux, D.; Verschueren, W.; Tahri, A.; Ghosh, A.; Yoshimura, K.; Mitsuya, H. A Femtomolar HIV-1 Protease Inhibitor with Subnanomolar Activity against Multidrug Resistant HIV-1 Strains. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago, Illinois. Abstract and presentation 12.
229. Rodriguez-French, A.; Nadler, J.P. The NEAT study: GW433908 efficacy and safety in antiretroviral therapy naïve subject, preliminary 24-week results. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, Abstract H-166.
230. Vertex Pharmaceuticals Press Release 2003. Available at: http://www.vrtx.com/Pressreleases2003.
231. Markowitz, M.; Hurley, A.; Ramratnam B.; Louie, M.; Kost, R.; Captan, B.; Pierce, A.; Shaefer, M.; Zhang, L.; Ho, D.D. The safety and efficacy of ritonavir-boosted amprenavir-based regimen after switch from amprenavir-based HAART. 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001, Chicago, Illinois, Abstract 405.
232. Functional Genetics, the genetic advantages to drug discovery, 2002. Available at: http://www.functional-genetics.com.
233. Panacos Pharmaceuticals unveils the leading compound in a major new class of HIV drug candidates: Budding inhibitors; Gaithersburg, 2002 /PRNews wire. Available at: http://www.panacos.com/Buddinginhibitors.htm.
234. Vahlne, A. Tripeptide that inhibits HIV-1: discovery and mode of action. Ab-str. Meet., HIV Therapeutics: Searching for the Next Generation, Feb 28-Mar 1. London: SIM Group, 2001.
235. Freed, E.O. Virol., 1998, 251, 1.
236. Klimkait, T.; Strebel, K.; Hoggan, M.D.; Martin, M.A.; Orenstein, J.M. J. Virol., 1990, 64, 621.
237. Su, J.; Palm, A.; Wu, Y.; Sandin, S.; Hoglund, S.; Vahlne, A. AIDS Res. Hum. Retroviruses., 2000, 16, 37.
238. Su, J.; Andersson, E.; Horal, P.; Naghavi, M.H.; Palm, A.; Wu, Y.P.; Eriksson, K.; Jansson, M.; Wigzell, H.; Svennerholm, B.; Vahine, A. J. Hum. Virol., 2001, 4, 1.
239. Su, J.; Naghavi, M.H.; Jejcic, A.; Horal, P.; Furuta, Y.; Wu, Y.P.; Li, S.L.; Hall, W.W.; Goobar-Larsson, L.; Svennerholm, B.; Vahlne, A. J. Hum. Virol., 2001, 4, 8.
240. Gottfredsson, M.; Bohjanen, P.R. Frontiers in BioSci., 1997, 2, 619.
241. Dornburg, R.; Pomerantz, R.J. In: Immunotherapy for infectious diseases; Jacobson, J.M. Ed.; Humana press. Totowa, New Jersey, 2002; pp. 238-9.
242. Rusnati, M.; Presto, M. Drug of the fut., 2002, 27, 481.
243. Gategnol, A.; Jeang, K.T. Adv. Pharmacol., 2000, 48, 209.
244. Noonan, D.; Albini, A. Adv. Pharmacol., 2000, 48, 229.
245. Haubrich, R.H.; Flexner, C.; Lederman, M.M.; Hirsch, M.; Pettinelli, C.P.; Ginsberg, R.; Lietman, P.; Hamzeh, F.M.; Spector, S.A.; Richman, D.D. J. Infect. Dis., 1995, 172, 1246.
246. Arzumanov, A.; Walsh, A.P.; Liu, X.; Rajwanshi, V.K.; Wengel, J.; Gait, M.J. Nucleos. Nucleot. Nucl. Aci., 2001, 20, 471.
247. Arzumanov, A.; Walsh, A.P.; Rajwanshi, V.K.; Kumar, R.; Wengel, J.; Gait, M.J. Biochemist., 2001, 40, 14645.
248. Chang, H.K.; Gendelman, R.; Lisziewicz, J.; Gallo, R.C.; Ensoli, B. Gene Ther., 1994, 1, 208.
249. Lee, S.W.; Gallardo, H.F.; Gaspar, O.; Smith, C.; Gilboa, E. Gene Ther., 1995, 2, 377.
250. Jayan, G.C.; Cordelier, P.; Patel, C.; BouHamdan, M.; Johnson, R.P.; Lisziewicz, J.; Pomerantz, R.J.; Strayer, D.S. Gene Ther., 2001, 8, 1033.
251. Bohjanen P.R.; Colvin, R.A.; Puttaraju, M.; Been, M.D.; Garcia-Blanco, M.A. Nucleic Acids Res., 1996, 24, 3733.
252. Ulich, C.; Harrich, D.; Estes, P.; Gaynor, R.B. J. Virol., 1996, 70, 4871.
253. Orsini, M..J.; Debouck, C.M. J. Virol., 1996, 70, 8055.
254. Rossi, C.; Balboni, P.G.; Betti, M.; Marconi, P.C.; Bozzini, R.; Grossi, M.P.; Barbanti-Brodano, G.; Caputo, A. Gene Ther., 1997, 4, 1261.
255. Fraisier, C.; Abraham, D.A.; van Oijen, M.; Cunliffe, V.; Irvine, A.; Craig, R.; Dzierzak, E.A. Gene Ther., 1998, 5, 946.
256. Dassonneville, L.; Hamy, F.; Colson, P.; Houssier, C.; Bailly, C. Nucl. Aci. Res., 1997, 25, 4487.
257. Mischiati, C.; Jeang, K.T; Feriotto, G.; Breda, L.; Borgatti, M.; Bianchi, N.; Gambari, R. Antise. Nucl. Acid Drug Dev., 2001, 11, 209.
258. Lapidot, A.; Ben-Asher, E.; Eisenstein, M. FEBS Lett., 1995, 367, 33.
259. Poznansky, M.C.; La Vecchio, J.; Silva-Arietta, S.; Porter-Brooks, J.; Brody, K.; Olszak, I.T.; Adams, G.B.; Ramstedt, U.; Marasco, W.A.; Scadden, D.T. Hum Gene Ther., 1999, 10, 2505.
260. Marasco, W.A.; LaVecchio, J.; Winkler, A. J. Immunol. Meth., 1999, 231, 223.
261. Mhashilkar, A.M.; LaVecchio, J.; Eberhardt, B.; Porter-Brooks, J.; Boisot, S.; Dove, J.H.; Purnphrey, C.; Li, X.; Weissmahr, R.N.; Ring, D.B.; Ramstedt, U.; Marasco, W.A. Hum. Gene Ther., 1999, 10, 1453.
262. Jeang, K.T.; Xiao, H.; Rich, E.A. Tat. J. Biol. Chem., 1999, 274, 28837.
263. Gatignol, A.; Jeang, K.T. Adv. Pharmacol., 2000, 48, 209.
264. Friedler, A.; Friedler, D.; Luedtke, N.W.; Tor, Y.; Loyter, A.; Gilon, C. J. Biol. Chem., 2000, 275, 23783.
265. Chao, S.H.; Fujinaga, K.; Marion, J.E.; Taube, R.; Sausville, E.A.; Senderowicz, A.M.; Peterlin, B.M.; Price, D.H. J. Biol. Chem., 2000, 275, 28345.
266. Okamoto, H.; Cujec, T.P.; Peterlin, B.M.; Okamoto, T. Virol., 2000, 270, 337.
267. Majello, B.; De Luca, P.; Hagen, G.; Suske, G.; Lania, L. Nucl. Aci. Res., 1994, 22, 4914.
268. Gnabre, J.N.; Brady, J.N.; Clanton, D.J.; Ito Y.; Dittmer, J.; Bates, R.B.; Huang, R.C. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 11239.
269. Kirk, S. J. Amer. Chem. Soc., 2000, 122, 980.
270. Pavia, A.T. Novel Approaches to the inhibition of HIV. The body Covers. The 42nd Interscience Conference on Antimicrobial Agents and Chemotherpay (ICAAC), September 30 2002.
271. Lamothe, B.; Joshi, S. Front. BioSci., 2000, 1, D527.
272. Malim, M.H.; Bohnlein, S.; Fenrick, R.; Le, S.Y.; Maizel, J.V.; Cullen, B.R. Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 8222.
273. Escaich, S.; Kalfoglou, C.; Plavec, I.; Kausbal, S.; Mosca, J.D.; Bohnlein, E. Hum. Gene Ther., 1995, 6, 625.
274. Liu, J.; Woffendin, C.; Yang, Z.Y.; Nabel, G.J. Gene Ther., 1994, 1, 32.
275. Malim, M.H.; Freimuth, W.W.; Liu, J.; Boyle, T.J.; Lyerly, H.K.; Cullen, B.R.; Nabel, G.J. J. Exp. Alled., 1992, 176, 1197.
276. Ragheb, J.A.; Bressler, P.; Daucher, M.; Chiang, L.; Chuah, M.K.; Vandendriessche, T.; Morgan, R.A. AIDS Res. Hum. Retrovir., 1995, 11, 1343.
277. Woffendin, C.; Yang, Z.Y.; Udaykumar, Xu, L.; Yang, N.S.; Sheehy, M.J.; Nabel, G.J. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 11581.
278. Woffendin, C.; Ranga, U.; Yang, Z.; Xu, L.; Nabel, G.J. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 2889.
279. Nabel, G.J.; Fox, B.A.; Post, L.; Thompson, C.B.; Wofferdin, C. Hum. Gene Ther., 1994, 79, 92.
280. Plavec, I.; Agarwal, M.; Ho, K.E.; Pineda, M.; Auten, J.; Baker, J.; Matsuzaki, H.; Escaich, S.; Bonyhadi, M.; Bohnlein, E. Gene Ther., 1997, 4, 128.
281. Qian, X.Y.; Chen, Z.Y.; Zhang, J.; Rabson, A.B.; Krug, R.M. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 8873.
282. Li, G.; Lisziewicz, J.; Sun, D.; Zon, G.; Daefler, S.; Wong-Staal, F.; Gallo, R.C.; Klotman, M.E. J. Virol., 1993, 67, 6882.
283. Lisziewicz, J.; Sun, D.; Klotman, M.; Agrawal, S.; Zamecnik, P.; Gallo, R. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 11209.
284. Sczakiel, G.; Oppenlander, M.; Rittner, K.; Pawlita, M. J Virol., 1992, 66, 5576.
285. Bahner, I.; Kearns, K.; Hao, Q.L.; Smogorzewska, E.M.; Kohn, D.B. J Virol., 1996, 70, 4352.
286. Lee, T.C.; Sullenger, B.A.; Gallardo, H.F.; Ungers, G. E.; Gilboa, E. New Biol., 1992, 4, 66.
287. Lee, S. W.; Gallardo, H.F.; Gilboa, E.; Smith, C. J. Virol., 1994, 68, 8254.
288. Smith, C.; Lee, S. W.; Wong, E.; Gallardo, H.; Page, K.; Gaspar, O.; Lebkowski, J.; Gilboa, E. Antiviral Res., 1996, 32, 99.
289. Good, P.D.; Krikos, A.J.; Li, S.X.; Bertrand, E.; Lee, N.S.; Giver, L.; Ellington, A.; Zaia, J.A.; Rossi, J.J.; Engelke, D.R. Gene Ther., 1997, 4, 45.
290. Gottfredsson, M.; Gentry, T.; Phillips, K.; Hull, S.; Gilboa, E.; Smith, C. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. 1996, Abstract 115.
291. Duan, L.; Zhang, H.; Oakes, J.W.; Bagasra, O.; Pomerantz, R.J. Hum. Gene Ther., 1994, 5, 1315.
292. Duan, L.; Bagasra, O.; Laughlin, M.A.; Oakes, J.W.; Pomerantz, R.J. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 5075.
293. Wu, Y.; Duan, L.; Zhu, M.; Hu, B.; Kubota, S.; Bagasra, O.; Pomerantz, R.J. J. Virol., 1996, 70, 3290.
294. Kubota, S.; Duan, L.; Furuta, R.A.; Hatanaka, M.; Pomerantz, R.J. J Virol., 1996, 70, 1282.
295. Ding, S.F.; Lombardi, R.; Nazari, R.; Sadhna, J. Frontiers in BioSci., 2002, 7, a15.
296. Zhao, L.J. 2002. Available at: http://medschool.slu.edu/mmi/new/fac/zhao.phtml.
297. Shee A. The identification of cellular host factors that contribute to the HIV-1 vif pheontype. XIV International AIDS conference, July 2002, Barcelona, Spain, Abstract 128.
298. Datta, H. J.; Glazer, P.M. Nucl. Aci. Res., 2001, 29, 5140.
299. Usman, N.; Blatt, L.M. J. Clin. Invest., 2000, 106, 1197.
300. Nishikura, K. Cell, 2001, 107, 415.
301. Tuschl, T. Nat. Biotechnol., 2002, 20, 446.
302. Elbashir, S.M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W.; Tuschi, T. EMBO J., 2001, 20, 6877.
303. Wong-Staal, F.; Poeschla, E.M.; Looney, D.J. Hum. Gene Ther., 1998, 9, 2407.
304. Amado, R.G.; Mitsuyasu, R.T.; Symonds, G.; Rosenblatt, J.D.; Zack, J.; Sun, L.Q.; Miller, M.; Ely, J.; Gerlach, W. Hum. Gene Ther., 1999, 10, 2255.
305. Jansen, B.; Wacheck, V.; Heere-Ress, E.; Schlagbauer-Wadl, H.; Hoeller, C.; Lucas, T.; Hoermann, M.; Hollenstein, U.; Wolff, K.; Pehamberger, H. Lanc., 2000, 356, 1728.
306. Tolcher, A.W. Semin. Oncol., 2001, 28, 67.
307. Luger, S.M.; O'Brien, S.G.; Ratajczak, J.; Ratajczak, M.Z.; Mick, R.; Stadtmauer, E.A.; Nowell, P.C.; Goldman, J.M.; Gewirtz, A.M. Blood, 2002, 99, 1150.
308. Cunningham, C.C.; Holmlund, J.T.; Geary, R.S.; Kwoh, T.J.; Dorr, A.; Johnston, J.F.; Monia, B.; Nemunaitis, J. Can., 2001, 92, 1265.
309. Rudin, C.M.; Holmlund, J.; Fleming, G.F.; Mani, S.; Stadler, W.M.; Schumm, P.; Monia, B.P.; Johnston, J.F.; Geary, R.; Yu, R.Z.; Kwoh, T.J.; Derr, F.A.; Ratain, M.J. Clin Cancer Res., 2001, 7, 1214.
310. Looney, D.; Yu, M. Methods Mol. Biol., 1997, 74, 469.
311. Brower, V.; Chahine, K.; Dorey, E.; Dove, A.; Francisco, M.; Hodgson, J.; Michael, A.; Marshall, A. Nat. Biotechnol., 1998, 16, 123.
312. Schreiber, S.; Nikolaus, S.; Malchow, H.; Kruis, W.; Lochs, H.; Raedler, A.; Hahn, E.G.; Krummenerl, T.; Steinmann, G. Gastroenterol., 2001, 120, 1339.
313. Wraight, C.J.; White, P.J.; McKean, S.C.; Fogarty, R.D.; Venables, D.J.; Liepe, I.J.; Edmondson, S.R.; Werther, G.A. Nat. Biotechnol., 2000, 18, 521.
314. Roque, F.; Mon, G.; Belardi, J.; Rodriguez, A.; Grinfeld, L.; Long, R.; Grossman, S.; Malcolm, A.; Zon, G.; Ormont, M.L.; Fischman, D.L.; Shi, Y.; Zalewski, A. Antisen. Nucl. Acid Drug Dev., 2001, 11, 99.
315. Kutryk, M.J.; Foley, D.P.; Van den Brand, M.; Hamburger, J.N.; Van der Giessen, W.J.; DeFeyter, P.J.; Bruining, N.; Sabate, M.; Serruys. P.W. J. Am. Coll. Cardiol., 2002, 39, 281.
316. Opalinska, J.B.; Gewirtz, A.M. Nat. Reviews Drug Discov., 2002, 1, 503.
317. Rigden, J.E.; Ely, J.A.; Macpherson, J.L.; Gerlach, W.L.; Sun, L-Q.; Symonds, G.P. Curr. Issues Mol. Biol., 2000, 2, 61.
318. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Nat., 1998, 391, 806.
319. Zamore, P.D.; Tuschl, T.; Sharp, P.A.; Bartel, D.P. Cell., 2000, 101, 25.
320. Ketting, R.F.; Haverkamp, T.H.; van Luenen, H.G.; Plasterk, R.H. Cell, 1999, 99, 133.
321. Tabara, H.; Hill, R.J.; Mello, C.C.; Priess, J.R.; Kohara, Y. Develop., 1999, 126, 1.
322. Jacque, J.M.; Triques, K.; Stevenson, M. Nat., 2002, 418, 435.
323. Hutvagner, G.; Zamore, P.D. Current Opin. Genet. Dev., 2002, 12, 225.
324. Elbashir, S.M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W.; Tuschl, T. EMBO J., 2001, 20, 6877.
325. Brummelkamp, T.R.; Bernards, R.; Agami, R. Sci., 2002, 296, 550.
326. Guo, H.S.; Ding, S.W. EMBO J., 2002, 21, 398.
327. Li, W.X.; Ding, S.W. Current Opin. Biotechnol., 2001, 12, 150.
328. Llave, C.; Kasschau, K.D.; Carrington, J.C. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 13401.
329. Lucy, A.P.; Guo, H.S.; Li, W.X.; Ding, S.W. EMBO J., 2000, 19, 1672.
330. Li, H.; Li, W.X.; Ding, S.W. Sci., 2002, 296, 1319.
331. Tuschl, T.; Borkhardt, A. Molecul. Interven., 2002, 2, 158.
332. Lee, N.S.; Dohjima, T.; Bauer, G.; Li, H.; Li, M.J.; Ehsani, A.; Salvaterra, P.; Rossi, J. Nat. Biotech., 2002, 20, 500.
333. Coburn, G.A.; Cullen, B.R. J. Virol., 2002, 76, 9225.
334. Ziwei, H. Pharmaco. and Theraput., 2000, 86, 201.
335. Zinc finger inhibitor for HIV. Clearinghouse, AIDS Newsletter Database, aidsline national library of medicine; Treat Rev., 1996 Dec, 23,13.
336. Goebel, F.D.; Hemmer, R.; Schmit, J.C.; Bogner, J.R.; de Clercq, E.; Witvrouw, M.; Pannecouque, C.; Valeyev, R.; Vandevelde, M.; Margery, H.; Tassignon, J.P. AIDS, 2001, 15, 33.
337. Science & Technology Corporation UNM web site: http://stc.unm.edu/portfolio/.
338. Scripps Research Institute-News and Views, Potential strategy against HIV, 2001, 1, Issue 13.
339. Edelson, S. BioCentury, The Bernstein Report on BioBusiness, November 4 2002, 1. Available at: http://www.achillion.com/achlln.pdf.
340. Alcorn, K. aidsmap, News, Agents found to attack two new steps in HIV life cycle, 5 January 2001; Available at: http://www.aidsmap.com/news.
341. Refer to Goebel, F.D. et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS, 2000, 15, 33.
342. Forbes, A. Commentaries, Community Research Initiative on AIDS, ACRIA Up Data, 2001, 10.
343. Joint United nations Program on HIV/AIDS (UNAIDS), Microbicides fro HIV prevention: UNAIDS technical update, Geneva: UNAIDS, 1998; and Family Health International (FHI), Microbicides/Spermicides: Opportunities for Industrial Collaboration. Summary of an International Conference, Research Triangle Park, NC: FHI, 1999.
344. Alliance for Microbicide Development, research and development status as of July 1999, Takoma Park, MD: Alliance for Microbicides development., 1999.
345. CDC, National center for HIV, STD and TB prevention, what we know about nonoxynol-9 for HIV and STD prevention. 1997. Available at: http://www.managingdesire.org/N9html.
346. Deirdre, W.; Jennifer, F.; Jacqueline, E. Darroch; Microbicides, a new defense against sexually transmitted diseases; The Alan Guttmacher Institute, 1999. Avaiable at: http://www.agi.usa.org.
347. HIV Prevention Trials Network. Available at: http://www.hptn.org/.
348. Pinto, L.A.; Shearer, G.M.; Blazevic, V. Clin. Immunol. 2000, 97, 1.
349. Progress against HIV: The need for new treatments for AIDS is more urgent than ever, Nat Biotechnology, 2000, 18 (Supplement),IT27. Reprinted from: Nat Biotechnol., 2000, 18, 466. Available at: http://biotech.nature.com.
350. Sean R. Hosein. Commentaries, Community research initiative on AIDS, ACRIA updata, 2001, 10.
351. Deirdre, D.; Scripture-Adams, D. G.; Brooks, Yael. D.; Zack, K.; Zack, J.A. IL7 induces expression of latent HIV-1 with minimal effects on T cell phenotype; Midwinter Conference of Immunologists, 2001.
352. Mastroianni, C.M.; Forcina, G.; d'Ettorre, G.; Lichtner, M.; Mengoni, F.; D'Agostino, C.; Vullo V. HIV Clin Trials., 2001, 2, 108.
353. McMichael, A.J.; Rowland-Jones, S.L. Nat., 2001, 410, 980.
354. Koup, R.A.; Safrit, J.T.; Cao, Y.; Andrews, C.A.; McLeod, G.; Borkowsky, W.; Farthing, C.; Ho, D.D. J. Virol., 1994, 68, 4650.
355. Kuroda, M.J.; Schmitz, J.E.; Charini, W.A.; Nickerson, C.E.; Lord, C.I.; Forman, M.A.; Letvin, N.L. J. Virol., 1999, 73, 1573.
356. Zhang, L.; Yu, W.; He, T.; Yu, J.; Caffrey, R.E.; Dalmasso, E.A.; Fu, S.; Pham, T.; Mei, J.; Ho, J.J.; Zhang, W.; Lopez, P.; Ho, D.D. Sci., 2002, 298, 995.
357. Levy, J.A.; Mackewicz, C.E.; Barker, E. Immunol Today., 1996, 17, 217.
358. Cao, Y.; Qin, L.; Zhang, L.; Safrit, J.; Ho, D.D. N. Engl. J. Med., 1995, 332, 201.
359. Barker, E.; Mackewicz, C.E.; Reyes-Teran, G.; Sato, A.; Stranford, S.A.; Fujimura, S.H.; Christopherson, C.; Chang, S.Y.; Levy, J.A. Blood, 1998, 92, 3105.
360. Mackewicz, C.E.; Ortega, H.W.; Levy, J.A. J. Clin. Invest., 1991, 87, 1462.
361. Levy, J. A. Commentaries, Community research initiative on AIDS, ACRIA updata, 2001, 10.
362. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Sci., 1995, 270, 1811.
363. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Nat., 1996, 381, 661.
364. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. Cell, 1996, 85, 1135.
365. Alkhatib, G.; Combadiere, C.; Broder, C.C.; Feng, Y.; Kennedy, P.E.; Murphy, P.M.; Berger, E.A. Sci., 1996, 272, 1955.
366. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. Sci., 1996, 272, 872.
367. Barker, E.; Bossart, K.N.; Levy, J.A. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 1725.
368. Moriuchi, H.; Moriuchi, M.; Combadiere, C.; Murphy, P.M.; Fauci, A.S. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 15341.
369. Lacey, S.F.; McDanal, C.B.; Horuk, R.; Greenberg, M.L. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 9842.
370. Lehrer, R.I.; Ganz, T. Curr. Opin. Immunol., 2002, 14, 96.
371. Agerberth, B.; Charo, J.; Werr, J.; Olsson, B.; Idali, F.; Lindbom, L.; Kiessling, R.; Jornvall, H.; Wigzell, H.; Gudmundsson, G.H. Blood., 2000, 96, 3086.
372. Diamond, D.L.; Kimball, J.R.; Krisanaprakornkit, S.; Ganz, T.; Dale, B.A. J. Immunol. Methods, 2001, 256, 65.